VectorBuilder, Inc.
$1Bpaper valuation
// OVERVIEW
VectorBuilder is the only gene therapy infrastructure company that turned plasmid design software into a $1 billion valuation by making it easier for academic researchers to order custom viral vectors online than to build them in-house. The company operates manufacturing facilities in the US and China, processing thousands of custom gene therapy vectors annually for research institutions and biotech companies that lack the internal capability to design and produce these tools themselves. What began as a design platform became a contract manufacturing business that sits at the foundation of the entire gene therapy development pipeline.
// HQ
Chicago, United States
// STATUS
PRIVATE
// FOUNDED
2016
// TIER
The Unicorn Herd · $1B – $9.9B
// PRIMARY SECTOR
biopharma
// FOUNDERS
// FUNDING ROUNDS
// SECTORS SERVED
// TECHNOLOGY
VectorBuilder's core offering is a web-based platform that allows researchers to design custom plasmids, viral vectors, and CRISPR constructs through a visual interface, then order them for delivery in 2-3 weeks. The platform automates sequence optimization, regulatory element selection, and quality control checks that would typically require specialized molecular biology expertise. The company operates GMP-compliant manufacturing facilities capable of producing AAV, lentivirus, and adenovirus vectors at research and clinical scale.
// WOWLS ASSESSMENT
VectorBuilder captured a real market inefficiency — most academic labs and early-stage biotech companies cannot efficiently produce their own gene therapy vectors and the existing contract manufacturers were slow and expensive. The company processes over 40,000 vector orders annually and claims to serve more than 10,000 research institutions globally. The $1 billion valuation assumes this manufacturing infrastructure becomes indispensable as gene therapy moves from research to commercial scale. The vulnerability is that VectorBuilder's customers are primarily academic researchers and pre-clinical biotech companies — the moment a gene therapy candidate advances to late-stage clinical trials or commercialization, the sponsor typically brings vector manufacturing in-house or contracts with a larger CDMO like Lonza or Catalent that can guarantee regulatory compliance and commercial-scale production. VectorBuilder is building the tools that help create the gene therapies that will eventually outgrow needing VectorBuilder.
// WHY WOWLS HUNTS THIS
The company solved the right problem for early-stage gene therapy development and captured meaningful market share, but the business model depends on customers staying small and under-resourced forever. Every successful gene therapy that VectorBuilder helped develop becomes a customer that no longer needs VectorBuilder.
// VALUATION NOTE
Limited public financial data available. Valuation based on private funding rounds with participation from Chinese and US venture investors. Manufacturing facility locations and production capacity estimates derived from company materials and industry sources.
VERDICT: ARMED — VECTORBUILDER MANUFACTURES 40,000 CUSTOM GENE THERAPY VECTORS ANNUALLY FOR RESEARCHERS WHO WILL EVENTUALLY BUILD THEIR OWN MANUFACTURING ONCE THEIR THERAPIES REACH COMMERCIAL SCALE
// PACK DEBATE
// PACK DEBATE — be the first to weigh in
Google account required — no spam, no nonsense
// LOADING INTEL…
// BROADCAST INTEL
// SIMILAR TARGETS
No peers logged yet.
// INTEL UPDATED: MAY 2026
// INTELLIGENCE DISCLAIMER: Assessments represent editorial opinion based on publicly available data including filings, press reports, and market data as of the date shown. Valuations are approximate. Not financial or investment advice.
// FULL NETWORK ACCESS
🚀 Founder Briefing: Instantly sort investors by Sector, Stage, & Round — direct links to websites for all 1,030 unicorns & backing VCs included.
Don't just track VectorBuilder, Inc..
Master the entire 1,030 unicorn company intelligence network.
Stop analyzing tech monopolies one page at a time. Instantly filter, sort, and isolate the exact venture capital firms, angel investors, and corporate funds backing your specific market vertical. Find investors that fit your sector and deploy your pitch with direct outbound links to every target asset in the database — 1,030 targets total.
Acquire Intel →// 5 TIERS · PAYPAL SECURED
// ENGAGE THE FULL ARSENAL
Done reading on VectorBuilder, Inc.?
Unlock the entire 1,030-company hitlist and 1,030 investor contacts.
Full structural breakdowns. Founder dossiers. VC outreach data. Threat-level intel updated continuously.
→ Deploy 5-Tier Order Form// ARBAN · ZUUN · MINGHAN · TUMEN · KHAN